Cell & Gene Therapy development

  • Five competencies for operational excellence in cell and gene therapy clinical trials

    Five competencies for operational excellence in cell and gene therapy clinical trials

    Read More
  • ×

    Let's start a conversation...

    First Name
    Last Name
    Job Title
    Company Name
    Country
    Therapeutic Area Interest - optional
    Tell us how we can help
    Thank you! We'll be in touch soon.
    Error - something went wrong!
  • Regulatory considerations from former FDA regulators

    Regulatory considerations from former FDA regulators

    In this infographic, we’ve compiled some common questions our ex-FDA experts get asked, along with their perspectives.

    Learn More
  • Payer insights for cell and gene therapies2:29

    Payer insights for cell and gene therapies

    It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treat

    Watch Video
  • Dosing strategies for gene therapies

    Dosing strategies for gene therapies

    In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for competitively positioning your gene therapy.

    Read More
  • CAR-T: A patient’s cell therapy success story7:35

    CAR-T: A patient’s cell therapy success story

    Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encourage participation in these trials? Doug Olson, one of the first CAR-T patients treated on a

    Watch Video
  • The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy

    The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy

    In 2020, ASCO went virtual for the first time. While the format was different, one thing was clear: despite all that is happening in the world, there are still many patients in need. Todd Shuster,...

    Learn More
  • The Evolving Cell and Gene Therapy (CGT) Sector in China

    The Evolving Cell and Gene Therapy (CGT) Sector in China

    Learn More
  • COVID-19 and the effect on cellular therapy trials

    COVID-19 and the effect on cellular therapy trials

    In clinical trials for cellular and gene therapies, the COVID-19 pandemic has created enormous complexities. Parexel experts Matthew M. Cooney, MD and Roberta L. Steere offer a brief overview.

    Learn More
  • CMC Considerations for Gene Therapy and Regenerative Medicine Studies

    CMC Considerations for Gene Therapy and Regenerative Medicine Studies

    Learn More
  • Former FDA expert provides valuable advice on INTERACT programs for CBER products

    Former FDA expert provides valuable advice on INTERACT programs for CBER products

    Many sponsors of CBER-regulated products are familiar with pre-IND meetings, but there’s a new program called INTERACT, which stands for Initial Targeted Engagement for Regulatory Advice on CBER...

    Learn More
  • Manufacturing Considerations for Cell and Gene Therapy Products to Mitigate the Risk of COVID-19 Disease Transmission

    Manufacturing Considerations for Cell and Gene Therapy Products to Mitigate the Risk of COVID-19 Disease Transmission

    Cell and gene therapies embrace a wide variety of products including: 1) autologous and allogeneic off-the-shelf cellular products; 2) gene modified autologous and allogeneic off-the-shelf...

    Learn More
  • Establishing Manufacturing Controls: A Hurdle for the Cell and Gene Therapy Industry

    Establishing Manufacturing Controls: A Hurdle for the Cell and Gene Therapy Industry

    Learn More
  • Bioprocessing and Biologics risk from Coronavirus

    Bioprocessing and Biologics risk from Coronavirus

    Coronavirus COVID-19 has been all over the news recently.  This virus is part of a larger family called Coronaviridae, which includes viruses that can infect only animals, cause mild colds...

    Learn More
  • CAR-T: How far have we come and where are we going?

    CAR-T: How far have we come and where are we going?

    In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days....

    Learn More
  • How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

    How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

    The UK national health technology assessment (HTA) body, the National Institute for Health and Clinical Excellence (NICE), made a long-awaited announcement last week: NICE has expanded the...

    Learn More
  • Beware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!

    Beware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!

    Donor Eligibility (DE) determination is a central aspect of how FDA and other regulatory authorities ensure that a product from a single allogeneic donor has acceptable very low risk of...

    Learn More
  • Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring

    Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring

    What is KASA and why does FDA need it? Due to issues stemming from the large volume of generic drug applications submitted to the agency and the fact that some of the submissions are have...

    Learn More
  • Commercializing Gene and Cellular Therapy

    Commercializing Gene and Cellular Therapy

    Gene and cellular therapy manufacturing requires strict control in current Good Manufacturing Practice (cGMP) facilities.  Designing a facility or finding a contract manufacturer to meet the...

    Learn More
  • Criticality of Institutional Biosafety Committee for Clinical Studies of Cell and Gene Therapy Products

    Criticality of Institutional Biosafety Committee for Clinical Studies of Cell and Gene Therapy Products

    Conducting clinical trials for innovative gene therapy products that include viral vector-based products and gene-modified cells is not entirely straightforward.  Operationally, there are...

    Learn More
  • The State of Germline Gene Editing. What We Don’t Know!

    The State of Germline Gene Editing. What We Don’t Know!

    Learn More
  • loading
    Loading More...